Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation

PURPOSE: Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved for use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial to reduce prescribed radiation in children and adolescents with classical HL. METHODS: Open-label, single-arm, multicen...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Metzger, Monika L., Link, Michael P., Billett, Amy L., Flerlage, Jamie, Lucas, John T., Mandrell, Belinda N., Ehrhardt, Matthew J., Bhakta, Nickhill, Yock, Torunn I., Friedmann, Alison M., de Alarcon, Pedro, Luna-Fineman, Sandra, Larsen, Eric, Kaste, Sue C., Shulkin, Barry, Lu, Zhaohua, Li, Chen, Hiniker, Susan M., Donaldson, Sarah S., Hudson, Melissa M., Krasin, Matthew J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Wolters Kluwer Health 2021
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8260923/
https://ncbi.nlm.nih.gov/pubmed/33826362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.03286
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi